Posts Tagged ‘qPCR’
Bio-Rad Laboratories, Inc. announced it has received the Frost & Sullivan 2012 North American Market Penetration Leadership Award in Quantitative and Digital PCR Instrumentation. This annual award honors the company that has demonstrated excellence by growing market share at the fastest rate in its industry, as measured by revenues or units sold.
Frost & Sullivan, a global growth consulting company, cited findings from its best practices research that show Bio-Rad has built a solid reputation in amplification technologies. According to Frost & Sullivan’s research, Bio-Rad continually releases innovative products to earn customer loyalty and gain market share, with particularly strong market positions in both the real-time PCR (qPCR) and digital (dPCR) instrumentation markets.
“Bio-Rad clearly exhibits some of the key traits shared by the most successful companies: the ability to locate and solve unmet needs in the markets they serve and a dedication to continuous R&D,” said Christi Bird, life sciences senior industry analyst at Frost & Sullivan. “Bio-Rad’s commitment to innovation, coupled with its keen focus on other qualities valued most by its customers, has resulted in a strong and growing market position that makes the company an ideal recipient of this year’s Frost & Sullivan Market Penetration Leadership Award.”
“We are honored to receive recognition of our leadership in the real-time and digital PCR markets,” said Rachel Scott, amplification instruments business unit marketing manager at Bio-Rad. “The Frost & Sullivan award is a reflection of how we strive to develop innovative new solutions that align with the needs of the research community in terms of both technology and pricing.”
In the dPCR market, Frost & Sullivan believes the QX100™ Droplet Digital™ PCR system holds the greatest promise of all dPCR instruments currently on the market, due to its simplicity, performance, and affordability. The QX100 system has already received significant attention from pharmaceutical companies and cancer research laboratories, leading Frost & Sullivan to believe that the instrument will be the early market leader in the expanding dPCR market.
“Bio-Rad has also seen a great deal of interest from the growing molecular diagnostic market,” said James Lee, Droplet Digital PCR commercialization marketing manager at Bio-Rad. “We plan to participate in this market in the near future using our ddPCR™ technology.”
Bio-Rad was honored with this recognition at Frost & Sullivan’s 2012 Excellence in Best Practices Awards Banquet on November 8 in San Antonio, Texas. The event highlighted companies, strategies, processes, and executives that have achieved world-class performance within their industries.
For more information about Bio-Rad’s PCR products, visit http://bit.ly/PCR_Products.
Recorded from a live webinar.
Cytogenic studies over the past 50 years have hinted at the impact that copy number variations (CNVs) can have on phenotypic traits and disease susceptibility. Given the high incidence and clinical impact of CNVs, a precise, rapid and cost-effective method is needed for high-throughput validation of candidate CNV associations and for subsequent routing deployment in diagnostic settings. The predominant method used to validate CNVs in larger population is real-time or quantitative PCR (qPCR), which measures the relative rates of fluorescence increases during the exponential amplification of target and single-copy reference genes. The accuracy and precision of these measurements can be impacted by multiple factors including differences in amplification rates between the target and reference genes, variations in their amplification rates during qPCR, sampling error due to DNA concentration and analysis errors. Weaver et al. rigorously characterized these factors and found that systemic errors can be addressed by increasing the number of replicates to achieve the desired precision. however, the required number of replicates increases rapidly as finer discrimination is desired, with four replicates required to distinguish a twofold difference and up to 18 replicates to distinguish a 1.25-fold difference.
Read Digital PCR – Probing Copy Number Variations Using Bio-Rad’s QX100 Droplet Digital PCR System to learn more on how droplet digital PCR (ddPCR) can be used to determine small fold differences for higher-order CNV states.
Well…you heard it here first folks. Last week we told you about Bio-Rad Laboratories new line of pre-validated, MIQE friendly qPCR assays and how this is bound to save researchers troubleshooting time and frustration (see MIQE Trouble-Free). Now the story has made the news. According to the story on GenomeWeb, Bio-Rad’s launch of PrimePCR has given the company the distinct advantage of being the only vendor whose entire portfolio of qPCR assays has been validated to such standards. The company expects the assays, which cover approximately 95 percent of the human transcriptome, to save researchers time and resources by obviating the need to validate assays in their own laboratories.
Click here to read the rest of the story (subscription required).